BioCentury | Mar 22, 2018
Company News

An omnibus win for Omeros

...of Representatives may offer Omeros Corp. (NASDAQ:OMER) a lifeline for its struggling cataract surgery drug Omidria...
...on Oct. 1 for certain drugs whose status had expired on Dec. 31, 2017, including Omidria...
...resolution on Omidria's reimbursement status and that the company was seeking congressional and administrative solutions. Mary Romeo Omidria Omeros...
BioCentury | Nov 30, 2017
Company News

Omeros, Par settle Omidria patent infringement lawsuit

...Pharmaceuticals Inc. settled a patent infringement lawsuit concerning Par's proposed generic version of Omeros' Omidria ketorolac/phenylephrine...
...generic Omidria. Omeros granted Par a non-exclusive, non-sublicensable license to make, sell and distribute generic Omidria...
...between the permitted launch date and Oct. 23, 2033, when the last U.S. patent covering Omidria...
BioCentury | Nov 10, 2017
Company News

Omeros soars on single Phase III plan for OMS721

...loss per share of $0.33 on revenues of $17.7 million. The company markets ophthalmic drug Omidria...
...August, Omeros raised $63.6 million in a follow-on (see BioCentury Extra, Aug. 15) . Jaime De Leon ketorolac/phenylephrine Omidria OMS302 OMS721 Omeros...
BioCentury | Aug 18, 2017
Financial News

Omeros raises $68.3M in follow-on

...MASP2) has breakthrough therapy designation from FDA for IgA nephropathy. Omeros also markets ophthalmic drug Omidria...
...which combines anti-inflammatory agent ketorolac and pupil-dilating agent phenylephrine. Omeros Corp. (NASDAQ:OMER), Seattle, Wash. Mary Romeo Omidria OMS721 Omeros...
BioCentury | Aug 15, 2017
Financial News

Omeros, Oxford Immunotec fall after pricing follow-ons

...MASP2) has breakthrough therapy designation from FDA for IgA nephropathy. Omeros also markets ophthalmic drug Omidria...
BioCentury | Aug 11, 2016
Financial News

Amarin, Omeros fall after follow-ons

...MASP-2) to treat patients with atypical hemolytic uremic syndrome (aHUS). It also markets ophthalmic drug Omidria...
BioCentury | Mar 9, 2016
Company News

Omeros rises after laying out aHUS therapy plans

...released after market close on Monday, Omeros said 2015 sales of ophthalmic drug Omidria ( OMS302...
BioCentury | Nov 2, 2015
Company News

Omeros sales and marketing update

...an expanded access program to provide reimbursement assistance for cataract surgery patients on Omidria . Omidria...
...have insufficient commercial insurance will pay $30 out-of-pocket under the “We Pay the Difference” program. Omidria...
BioCentury | Jun 8, 2015
Clinical News

Omidria regulatory update

...EMA’s CHMP recommended approval of Omidria phenylephrine/ketorolac to maintain intraoperative mydriasis (pupil size), prevent intraoperative miosis...
...in the U.S. (see BioCentury, April 13). Omeros Corp. (NASDAQ:OMER), Seattle, Wash. Product: Omidria ( OMS302...
BioCentury | Apr 13, 2015
Company News

Omeros sales and marketing update

...Omeros launched Omidria in the U.S. to maintain intraoperative mydriasis (pupil size) by preventing intraoperative miosis...
Items per page:
1 - 10 of 61